Cargando…
Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy
Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower B...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412489/ https://www.ncbi.nlm.nih.gov/pubmed/36014894 http://dx.doi.org/10.3390/nu14163388 |
_version_ | 1784775506704465920 |
---|---|
author | Ning, Kang Li, Zhen Liu, Huiming Tian, Xi Wang, Jun Wu, Yi Xiong, Longbin Zou, Xiangpeng Peng, Yulu Zhou, Zhaohui Zhou, Fangjian Yu, Chunping Luo, Junhang Zhang, Hailiang Dong, Pei Zhang, Zhiling |
author_facet | Ning, Kang Li, Zhen Liu, Huiming Tian, Xi Wang, Jun Wu, Yi Xiong, Longbin Zou, Xiangpeng Peng, Yulu Zhou, Zhaohui Zhou, Fangjian Yu, Chunping Luo, Junhang Zhang, Hailiang Dong, Pei Zhang, Zhiling |
author_sort | Ning, Kang |
collection | PubMed |
description | Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower BMI. The role of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and perirenal fat thickness (PRFT) in mRCC patients was still unknown. Therefore, a multicenter retrospective study of 358 Chinese mRCC patients receiving anti-VEGF therapy was conducted and their body composition was measured via computed tomography. We parameterized VAT, SAT and PRFT according to their median value and BMI according to Chinese criteria (overweight: BMI ≥ 24). We found VAT, SAT, and PRFT (all p < 0.05) but not BMI, significantly associated with overall survival (OS) and progression-free survival (PFS). Multivariate Cox analysis identified PRFT was the independent predictor of OS and PFS, and IMDC expanded with PRFT showed the highest C-index in predicting OS (OS:0.71) compared with VAT, SAT, and BMI. PRFT could increase the area under the curve of the traditional International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in OS (70.54% increase to 74.71%) and PFS (72.22% increase to 75.03%). PRFT was introduced to improve the IMDC model and PRFT-modified IMDC demonstrated higher AIC in predicting OS and PFS compared with the traditional IMDC model. Gene sequencing analysis (n = 6) revealed that patients with high PRFT had increased angiogenesis gene signatures (NES = 1.46, p = 0.04) which might explain why better drug response to anti-VEGF therapy in mRCC patients with high PRFT. The main limitation is retrospective design. This study suggests body composition, especially PRFT, is significantly associated with prognosis in Chinese mRCC patients receiving anti-VEGF therapy. PRFT-modified IMDC model proposed in this study has better clinical predictive value. |
format | Online Article Text |
id | pubmed-9412489 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94124892022-08-27 Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy Ning, Kang Li, Zhen Liu, Huiming Tian, Xi Wang, Jun Wu, Yi Xiong, Longbin Zou, Xiangpeng Peng, Yulu Zhou, Zhaohui Zhou, Fangjian Yu, Chunping Luo, Junhang Zhang, Hailiang Dong, Pei Zhang, Zhiling Nutrients Article Although high body mass index (BMI) was reported to associate with a better prognosis for metastatic renal cell cancer (mRCC) patients receiving anti-vascular endothelial growth factor (anti-VEGF) therapy, it is an imperfect proxy for the body composition, especially in Asian patients with a lower BMI. The role of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT), and perirenal fat thickness (PRFT) in mRCC patients was still unknown. Therefore, a multicenter retrospective study of 358 Chinese mRCC patients receiving anti-VEGF therapy was conducted and their body composition was measured via computed tomography. We parameterized VAT, SAT and PRFT according to their median value and BMI according to Chinese criteria (overweight: BMI ≥ 24). We found VAT, SAT, and PRFT (all p < 0.05) but not BMI, significantly associated with overall survival (OS) and progression-free survival (PFS). Multivariate Cox analysis identified PRFT was the independent predictor of OS and PFS, and IMDC expanded with PRFT showed the highest C-index in predicting OS (OS:0.71) compared with VAT, SAT, and BMI. PRFT could increase the area under the curve of the traditional International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model in OS (70.54% increase to 74.71%) and PFS (72.22% increase to 75.03%). PRFT was introduced to improve the IMDC model and PRFT-modified IMDC demonstrated higher AIC in predicting OS and PFS compared with the traditional IMDC model. Gene sequencing analysis (n = 6) revealed that patients with high PRFT had increased angiogenesis gene signatures (NES = 1.46, p = 0.04) which might explain why better drug response to anti-VEGF therapy in mRCC patients with high PRFT. The main limitation is retrospective design. This study suggests body composition, especially PRFT, is significantly associated with prognosis in Chinese mRCC patients receiving anti-VEGF therapy. PRFT-modified IMDC model proposed in this study has better clinical predictive value. MDPI 2022-08-18 /pmc/articles/PMC9412489/ /pubmed/36014894 http://dx.doi.org/10.3390/nu14163388 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ning, Kang Li, Zhen Liu, Huiming Tian, Xi Wang, Jun Wu, Yi Xiong, Longbin Zou, Xiangpeng Peng, Yulu Zhou, Zhaohui Zhou, Fangjian Yu, Chunping Luo, Junhang Zhang, Hailiang Dong, Pei Zhang, Zhiling Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title | Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title_full | Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title_fullStr | Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title_full_unstemmed | Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title_short | Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy |
title_sort | perirenal fat thickness significantly associated with prognosis of metastatic renal cell cancer patients receiving anti-vegf therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412489/ https://www.ncbi.nlm.nih.gov/pubmed/36014894 http://dx.doi.org/10.3390/nu14163388 |
work_keys_str_mv | AT ningkang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT lizhen perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT liuhuiming perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT tianxi perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT wangjun perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT wuyi perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT xionglongbin perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT zouxiangpeng perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT pengyulu perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT zhouzhaohui perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT zhoufangjian perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT yuchunping perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT luojunhang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT zhanghailiang perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT dongpei perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy AT zhangzhiling perirenalfatthicknesssignificantlyassociatedwithprognosisofmetastaticrenalcellcancerpatientsreceivingantivegftherapy |